## Disclosure Statement

### Joint Working Project between;
- Weston Park Cancer Centre (WPCC) part of Sheffield Teaching Hospitals NHS Foundation Trust and Bristol-Myers Squibb Pharmaceuticals Ltd (BMS)

<table>
<thead>
<tr>
<th>Name of Project</th>
<th>Developing a robust, appropriate clinical review model for oncology patients who are off (systemic anti-cancer) treatment to detect relapse promptly and manage late effects of (novel) therapies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Overview</td>
<td>Demand for non-surgical cancer services is stretched – both activity and complexity are increasing. Projected increase in follow up activity is 3-8% over next 10 years which is likely to out-strip new referral rates as treatments are of increasingly longer duration and more complex, hence patients are seen for longer. The oncology workforce is challenged nationally; there is a national shortage of oncologists, and significant gaps within nursing and across all other specialities delivering and supporting cancer services. The current delivery model provides an inequitable service as patients are not able to access all treatments as close to their home as could be possible. Our vision is to deliver a safe, equitable and high-quality oncology service across South Yorkshire, Bassetlaw &amp; North Derbyshire (SYBND); delivering more treatment options closer to the patient. Patients will have access to appropriate expertise throughout their treatment pathway by modernising and enhancing the workforce model. This model will offer flexibility to meet variation in demand, will maximise research potential and reduces inequity of access to clinical trials. Ultimately, we aim to redesign our non-SACT assessment and delivery service to make it more accessible and responsive to patients and maximise health outcomes across the network. To date a strategic review of the SACT assessment and delivery service has been carried out across the SYBND network. This has provided valuable insights into the SACT service but also identified that there are additional clinical services that influence the delivery of SACT that now need to be evaluated. This includes clinical reviews of patients who have completed SACT and are on post treatment or long term follow up and patients who are pre and post radiotherapy.</td>
</tr>
</tbody>
</table>
| Project Objectives | 1. To analyse and understand the current pathways followed by patients who are not currently having systemic therapy  
2. To develop proposals needed to design a future service for non-SACT patients according to integrated system principles and incorporating secondary and primary care.  
3. To pilot one to two ‘proof of concept’ service proposals to understand the patient system and service benefit  
4. To deliver a final report which will include a set of service proposals developed as a result of the work undertaken throughout the project and agreed by the project board  

This proposal will sit within the current aims of the strategic group: to develop a strategic plan for the medical and non-medical workforce that supports the delivery of high-quality care, in an appropriate location close to the patient’s home. |
| Patient Benefits | • A service the meets the patient needs and is consistent with person centred values (for example: choice, control, independence, empowerment)  
• Improved patient experience through provision of a streamlined efficient and patient focused service  
• Improved patient experience and allaying some of the anxiety felt by some patients about post treatment symptoms and relapse signs |
| **Stakeholders** | Weston Park Cancer Centre (WPCC) part of Sheffield Teaching Hospitals NHS Foundation Trust  
Bristol Myers-Squibb Pharmaceuticals Ltd (BMS) |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Timelines</strong></td>
<td>The Project will start from the date on which the disclosure statement goes live on the BMS website and will finish 12 months after this date</td>
</tr>
</tbody>
</table>

Produced by **Bristol-Myers Squibb Pharmaceuticals Ltd (BMS)** with **Weston Park Cancer Centre (WPCC)**